Physician profile
David Tenembaum
NPI 1043453962
$22,392.61
in general payments reported to CMS, 2019-2025
21 companies · $954 in 2025
The $954 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $765 · 2020: $724 · 2021: $11K · 2022: $7,483 · 2023: $973 · 2024: $801 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,727.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $17,578.71 | 2019-2025 | Skyrizi, Linzess, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,561.03 | 2019-2025 | Xifaxan, Trulance |
| Redhill Biopharma INC. | $392.07 | 2020-2025 | Talicia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $292.04 | 2019-2021 | |
| Janssen Biotech, INC. | $268.61 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Ardelyx, INC. | $221.46 | 2023-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $212.59 | 2021-2023 | Linzess |
| Celgene Corporation | $168.52 | 2023-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $157.37 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $152.74 | 2020-2023 | Ocaliva |
| Gilead Sciences, INC. | $88.25 | 2019-2022 | |
| Amarin Pharma, INC. | $56.54 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.73 | 2024 | Entyvio |
| Lilly USA, LLC | $39.84 | 2020-2021 | |
| Cumberland Pharmaceuticals, INC. | $27.43 | 2019-2024 | Kristalose |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Concordia Pharmaceuticals INC. | $25.60 | 2019 | |
| Aimmune Therapeutics, INC. | $24.03 | 2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $21.12 | 2025 | Iqirvo |
| Vivus LLC | $19.05 | 2022 | |
| Exact Sciences Corporation | $18.68 | 2024 | Cologuard Collection Kit |
| Pfizer INC. | $18.20 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tenembaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.